| Jun 12 |
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
|
| Jun 11 |
Wolfe starts Madrigal at outperform, cites Rezdiffra launch
|
| Jun 10 |
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
|
| Jun 9 |
Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
|
| Jun 6 |
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
|
| Jun 5 |
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
|
| Jun 5 |
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
|
| Jun 5 |
Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 29 |
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
|
